A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti PD-1) INCAGN02385 (Anti LAG-3) and INCAGN02390 (Anti TIM-3) in Participants With Select Advanced Malignancies

Brief description of study

The purpose of the study is to determine safe combination doses and preliminary safety and efficacy for the combination of INCAGN02385, INCAGN02390, and INCMGA00012. INCMGA00012 is a monoclonal antibody targeting PD-1. INCAGN02385 is a monoclonal antibody targeting LAG-3. INCAGN02390 is a monoclonal antibody targeting TIM-3. INCAGN02385, INCAGN02390, and INCMGA00012 are investigational drugs, which means that they have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.

Clinical Study Identifier: s20-00260
ClinicalTrials.gov Identifier: NCT04370704

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.